Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 9675861, 8 pages
http://dx.doi.org/10.1155/2016/9675861
Research Article

Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus

1Division of Asthma, Allergy, and Rheumatology, Department of Pediatrics, Chang Gung Children’s Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan
2Department of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan
3Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
4Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
5Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan

Received 28 July 2016; Accepted 4 October 2016

Academic Editor: Junhui Wang

Copyright © 2016 Syh-Jae Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Renaudineau, J.-O. Pers, B. Bendaoud, C. Jamin, and P. Youinou, “Dysfunctional B cells in systemic lupus erythematosus,” Autoimmunity Reviews, vol. 3, no. 7-8, pp. 516–523, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Miyara, Z. Amoura, C. Parizot et al., “Global natural regulatory T cell depletion in active systemic lupus erythematosus,” The Journal of Immunology, vol. 175, no. 12, pp. 8392–8400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, “The biology of human natural killer-cell subsets,” Trends in Immunology, vol. 22, no. 11, pp. 633–640, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Cooper, T. A. Fehniger, S. C. Turner et al., “Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset,” Blood, vol. 97, no. 10, pp. 3146–3151, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. R. J. Green, A. S. M. Kennell, M. J. Larche, M. H. Seifert, D. A. Isenberg, and M. R. Salaman, “Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients,” Clinical and Experimental Immunology, vol. 141, no. 1, pp. 165–173, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Yabuhara, F.-C. Yang, T. Nakazawa et al., “A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus,” The Journal of Rheumatology, vol. 23, no. 1, pp. 171–177, 1996. View at Google Scholar · View at Scopus
  7. D. Schepis, I. Gunnarsson, M.-L. Eloranta et al., “Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus,” Immunology, vol. 126, no. 1, pp. 140–146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Hervier, V. Beziat, J. Haroche et al., “Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease,” Arthritis and Rheumatism, vol. 63, no. 6, pp. 1698–1706, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. I. Godfrey, H. R. MacDonald, M. Kronenberg, M. J. Smyth, and L. Van Kaer, “NKT cells: what's in a name?” Nature Reviews Immunology, vol. 4, no. 3, pp. 231–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Giroux and F. Denis, “CD1d-unrestricted human NKT cells release chemokines upon Fas engagement,” Blood, vol. 105, no. 2, pp. 703–710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Kokordelis, B. Krämer, C. Boesecke et al., “CD3(+)CD56(+) natural killer-like T cells display anti-HCV activity but are functionally impaired in HIV(+) Patients with acute hepatitis C,” Journal of Acquired Immune Deficiency Syndromes, vol. 70, no. 4, pp. 338–346, 2015. View at Publisher · View at Google Scholar
  12. A. Bojarska-Junak, I. Hus, M. Sieklucka et al., “Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome,” Oncology Reports, vol. 24, no. 3, pp. 803–810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. R. J. Green, A. S. M. Kennell, M. J. Larche, M. H. Seifert, D. A. Isenberg, and M. R. Salaman, “Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IgG production,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 303–310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. K. H. Grabstein, J. Eisenman, K. Shanebeck et al., “Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor,” Science, vol. 264, no. 5161, pp. 965–968, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. J. G. Giri, D. M. Anderson, S. Kumaki, L. S. Park, K. H. Grabstein, and D. Cosman, “IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2,” Journal of Leukocyte Biology, vol. 57, no. 5, pp. 763–766, 1995. View at Google Scholar · View at Scopus
  16. M. K. Kennedy, M. Glaccum, S. N. Brown et al., “Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice,” The Journal of Experimental Medicine, vol. 191, no. 5, pp. 771–780, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Baranda, H. de la Fuente, E. Layseca-Espinosa et al., “IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus,” Rheumatology, vol. 44, no. 12, pp. 1507–1513, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Aringer, G. H. Stummvoll, G. Steiner et al., “Serum interleukin-15 is elevated in systemic lupus erythematosus,” Rheumatology, vol. 40, no. 8, pp. 876–881, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Wais, W. Fierz, T. Stoll, and P. M. Villiger, “Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission,” The Journal of Rheumatology, vol. 30, no. 10, pp. 2133–2139, 2003. View at Google Scholar · View at Scopus
  20. P. Horák, V. Ščudla, Z. Heřmanová et al., “Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus,” Clinical Rheumatology, vol. 20, no. 5, pp. 337–344, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Fu, Z. Tian, and H. Wei, “Subsets of human natural killer cells and their regulatory effects,” Immunology, vol. 141, no. 4, pp. 483–489, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Zimmerman and F. J. Blanco, “Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action,” Current Pharmaceutical Design, vol. 14, no. 22, pp. 2128–2139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Peng, R. Sun, L. Tang, H. Wei, and Z. Tian, “CD62L is critical for maturation and accumulation of murine hepatic NK cells in response to viral infection,” The Journal of Immunology, vol. 190, no. 8, pp. 4255–4262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. I. Russell, D. S. C. Graham, S. Chadha et al., “No association between E- and L-selectin genes and SLE: soluble L-selectin levels do correlate with genotype and a subset in SLE,” Genes and Immunity, vol. 6, no. 5, pp. 422–429, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. T. K. Tso and W.-N. Huang, “Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: relation to insulin resistance,” The Journal of Rheumatology, vol. 34, no. 4, pp. 726–730, 2007. View at Google Scholar · View at Scopus
  26. M. Petri, “Review of classification criteria for systemic lupus erythematosus,” Rheumatic Disease Clinics of North America, vol. 31, no. 2, pp. 245–254, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Bombardier, D. D. Gladman, M. B. Urowitz, D. Caron, and C. H. Chang, “Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE,” Arthritis and Rheumatology, vol. 35, no. 6, pp. 630–640, 1992. View at Google Scholar
  28. T. Michel, A. Poli, A. Cuapio et al., “Human CD56bright NK cells: an update,” The Journal of Immunology, vol. 196, no. 7, pp. 2923–2931, 2016. View at Publisher · View at Google Scholar
  29. S.-J. Lin, P.-J. Cheng, T.-Y. Lin, P.-T. Lee, H.-S. Hsiao, and M.-L. Kuo, “Effect of influenza A infection on umbilical cord blood natural killer function regulation with interleukin-15,” Journal of Infectious Diseases, vol. 205, no. 5, pp. 745–756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S.-J. Lin, Y.-C. Huang, P.-J. Cheng, P.-T. Lee, H.-S. Hsiao, and M.-L. Kuo, “Interleukin-15 enhances the expansion and function of natural killer T cells from adult peripheral and umbilical cord blood,” Cytokine, vol. 76, no. 2, pp. 348–355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Henriques, L. Teixeira, L. Inês et al., “NK cells dysfunction in systemic lupus erythematosus: relation to disease activity,” Clinical Rheumatology, vol. 32, no. 6, pp. 805–813, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. F. M. Erkeller-Yuksel, P. M. Lydyard, and D. A. Isenberg, “Lack of NK cells in lupus patients with renal involvement,” Lupus, vol. 6, no. 9, pp. 708–712, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Hayakawa and M. J. Smyth, “CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity,” The Journal of Immunology, vol. 176, no. 3, pp. 1517–1524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. B. E. Freeman, H.-P. Raué, A. B. Hill, and M. K. Slifka, “Cytokine-mediated activation of NK cells during viral infection,” Journal of Virology, vol. 89, no. 15, pp. 7922–7931, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Comte, M. P. Karampetsou, and G. C. Tsokos, “T cells as a therapeutic target in SLE,” Lupus, vol. 24, no. 4-5, pp. 351–363, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. K. Ahn, H. Chung, D.-S. Lee, Y. S. Yu, and H. G. Yu, “CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behçet's uveitis,” The Journal of Immunology, vol. 175, no. 9, pp. 6133–6142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. K. Ahn, J.-M. Seo, J. Yu, F. S. Oh, H. Chung, and H. G. Yu, “Down-regulation of IFN-γ-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis,” Investigative Ophthalmology and Visual Science, vol. 46, no. 7, pp. 2458–2464, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S.-J. Lin and M.-L. Kuo, “Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function,” Cytotherapy, vol. 10, no. 4, pp. 397–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S.-J. Lin and D.-C. Yan, “ICAM-1 (CD54) expression on T lymphocytes and natural killer cells from umbilical cord blood: regulation with interleukin-12 and interleukin-15,” Cytokines, Cellular and Molecular Therapy, vol. 6, no. 4, pp. 161–164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. P. P. Sfikakis, D. Charalambopoulos, G. Vaiopoulos, and M. Mavrikakis, “Circulating P- and L-selectin and T-lymphocyte activation in patients with autoimmune rheumatic diseases,” Clinical Rheumatology, vol. 18, no. 1, pp. 28–32, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Font, P. Pizcueta, M. Ramos-Casals et al., “Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE),” Clinical and Experimental Immunology, vol. 119, no. 1, pp. 169–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Ma, H. Xiao, B. Marrero et al., “Combination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells,” Cellular Immunology, vol. 289, no. 1-2, pp. 140–144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Baslund, N. Tvede, B. Danneskiold-Samsoe et al., “Targeting interleukin-15 in patients with rheumatoid arthritis: A Proof-of-Concept Study,” Arthritis & Rheumatism, vol. 52, no. 9, pp. 2686–2692, 2005. View at Publisher · View at Google Scholar · View at Scopus